

MAGE-A10 (S-14): sc-324906

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-A10 (melanoma antigen family A, 10), also known as MAGE10 or CT1.10 (cancer/testis antigen 1.10), is a 369 amino acid protein that contains one MAGE domain and is thought to play a role in embryonic development and tumor progression. Like other members of the MAGE family, MAGE-A10 is expressed in head and neck squamous cell carcinoma, melanoma, breast cancer and lung cancer, suggesting that MAGE-A10 plays an important role in carcinogenesis.

REFERENCES

1. De Plaen, E., Arden, K., Traversari, C., Gaforio, J.J., Szikora, J.P., De Smet, C., Brasseur, F., van der Bruggen, P., Lethe, B. and Lurquin, C. 1994. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. *Immunogenetics* 40: 360-369.
2. Rogner, U.C., Wilke, K., Steck, E., Korn, B. and Poustka, A. 1995. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. *Genomics* 29: 725-731.
3. Rimoldi, D., Salvi, S., Reed, D., Coulie, P., Jongeneel, V.C., De Plaen, E., Brasseur, F., Rodriguez, A.M., Boon, T. and Cerottini, J.C. 1999. cDNA and protein characterization of human MAGE-10. *Int. J. Cancer* 82: 901-907.
4. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 300343. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
5. Lin, J., Lin, L., Thomas, D.G., Greenson, J.K., Giordano, T.J., Robinson, G.S., Barve, R.A., Weishaar, F.A., Taylor, J.M., Orringer, M.B. and Beer, D.G. 2004. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. *Clin. Cancer Res.* 10: 5708-5716.
6. Taylor, M., Bolton, L.M., Johnson, P., Elliott, T. and Murray, N. 2007. Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. *Breast Cancer Res.* 9: R46.
7. Andrade, V.C., Vettore, A.L., Felix, R.S., Almeida, M.S., Carvalho, F., Oliveira, J.S., Chauffaille, M.L., Andriolo, A., Caballero, O.L., Zago, M.A. and Colleoni, G.W. 2008. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. *Cancer Immun.* 8: 2.
8. Sartorius, R., Pisu, P., D'Apice, L., Pizzella, L., Romano, C., Cortese, G., Giorgini, A., Santoni, A., Velotti, F. and De Berardinis, P. 2008. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. *J. Immunol.* 180: 3719-3728.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: MAGEA10 (human) mapping to Xq28.

SOURCE

MAGE-A10 (S-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of MAGE-A10 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-324906 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

MAGE-A10 (S-14) is recommended for detection of MAGE-A10 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other MAGE-A family members.

Suitable for use as control antibody for MAGE-A10 siRNA (h): sc-108015, MAGE-A10 shRNA Plasmid (h): sc-108015-SH and MAGE-A10 shRNA (h) Lentiviral Particles: sc-108015-V.

Molecular Weight of MAGE-A10: 41 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.


 MONOS
Satisfation
Guaranteed

Try **MAGE-A (6C1): sc-20034**, our highly recommended monoclonal alternative to MAGE-A10 (S-14). Also, for AC, HRP, FITC, PE, Alexa Fluor® 488 and Alexa Fluor® 647 conjugates, see **MAGE-A (6C1): sc-20034**.